…
Longduoduo Company Limited, together its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company offers range of preventive healthcare services, including disease screening, healthcare treatments, healthcare products, and other services for the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases through third-party healthcare service providers, product suppliers, and sales agents. It also provides meridian-regulating and consciousness restoring iatrotechnics; double blood purification; immunological ozonated autohemotherapy; platelet-rich plasma; relaxation therapy; vegetative nerve regulation; and microwave therapy. The company was founded in 2020 and is headquartered in Hohhot, China.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Longduoduo Company Limited (LDDD.US) is quoted on the OTC Pink market and publicly available information does not clearly describe its core operations or financial condition. Major long-term growth drivers are not disclosed, so investors should monitor corporate filings, revenue sources and management credentials; the stock could attract those seeking speculative small-cap exposure if credible business information emerges.
Primary risks include low trading liquidity, minimal regulatory oversight typical of Pink-listed issuers, weak corporate governance and high information and execution risk that increase the likelihood of loss.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Income before tax | 0.71M | 1.89M | 0.03M | -7.56M | -0.38M |
| Minority interest | -0.03M | -0.11M | -0.06M | 0.05M | 0.05M |
| Net income | 0.46M | 1.26M | -0.04M | -7.52M | -0.33M |
| Selling general administrative | 3.62M | 5.19M | 3.20M | 9.79M | 0.70M |
| Gross profit | 4.17M | 7.22M | 3.23M | 2.23M | 0.32M |
| Reconciled depreciation | 0.14M | 0.10M | 0.07M | 0.07M | 0.00M |
| Ebit | 0.71M | 1.89M | - | -7.56M | -0.38M |
| Ebitda | 0.85M | 1.99M | - | -7.49M | -0.38M |
| Depreciation and amortization | 0.14M | 0.10M | - | - | - |
| Operating income | 0.55M | 2.03M | 0.03M | -7.56M | -0.38M |
| Other operating expenses | 3.71M | 5.36M | - | - | - |
| Tax provision | 0.22M | 0.52M | 0.01M | 0.00M | 0.00M |
| Income tax expense | 0.22M | 0.52M | - | 0.00M | - |
| Total revenue | 4.26M | 7.39M | 3.82M | 3.24M | 0.41M |
| Total operating expenses | 3.62M | 5.19M | 3.79M | 10.79M | 0.79M |
| Cost of revenue | 0.09M | 0.17M | 0.59M | 1.01M | 0.09M |
| Total other income expense net | 0.16M | -0.14M | 0.00M | -0.01M | 0.00M |
| Net income from continuing ops | 0.49M | 1.36M | 0.02M | -7.56M | -0.38M |
| Net income applicable to common shares | - | - | - | -7.52M | -0.33M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Total assets | 2.13M | 2.06M | 1.48M | 0.61M | 0.51M |
| Other current assets | 0.13M | 0.12M | - | 0.03M | 0.04M |
| Total liab | 0.83M | 1.28M | 2.05M | 1.63M | 0.90M |
| Total stockholder equity | 1.18M | 0.70M | -0.54M | -0.93M | -0.33M |
| Other current liab | 0.08M | 0.17M | 0.13M | 1.28M | 0.51M |
| Common stock | 0.03M | 0.03M | - | 0.30M | 0.16M |
| Capital stock | 0.03M | 0.03M | 0.03M | 0.30M | 0.16M |
| Retained earnings | -6.17M | -6.63M | -7.89M | -7.85M | -0.33M |
| Cash | 1.64M | 1.40M | 1.14M | 0.36M | 0.27M |
| Total current liabilities | 0.83M | 1.26M | 2.05M | 1.63M | 0.86M |
| Current deferred revenue | 0.34M | 0.71M | - | - | - |
| Net debt | -1.62M | -1.37M | - | - | - |
| Short term debt | 0.02M | 0.02M | - | - | - |
| Short long term debt | - | - | - | 0.14M | - |
| Short long term debt total | 0.02M | 0.04M | - | - | - |
| Other stockholder equity | 7.25M | 7.25M | - | 0.02M | -0.17M |
| Property plant equipment | - | - | - | 0.19M | 0.16M |
| Total current assets | 1.81M | 1.66M | 1.31M | 0.42M | 0.36M |
| Net tangible assets | - | - | - | -0.93M | -0.33M |
| Net receivables | 0.04M | 0.13M | - | 0.03M | 0.04M |
| Inventory | - | 0.00M | 0.00M | 0.00M | 0.00M |
| Accounts payable | 0.40M | 0.36M | 1.04M | 0.04M | 0.18M |
| Accumulated other comprehensive income | 0.08M | 0.06M | - | - | - |
| Non current assets total | 0.31M | 0.40M | 0.17M | 0.19M | 0.16M |
| Capital lease obligations | 0.02M | 0.04M | 0.01M | 0.04M | 0.09M |
| Breakdown | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 |
| Investments | -0.06M | -0.31M | -0.13M | -0.11M | -0.07M |
| Change to liabilities | - | - | - | 0.24M | 0.62M |
| Total cashflows from investing activities | -0.06M | -0.31M | - | -0.11M | -0.07M |
| Net borrowings | 0.00M | 0.00M | - | 0.15M | 0.15M |
| Total cash from financing activities | 0.00M | 0.00M | -0.14M | 0.18M | 0.18M |
| Change to operating activities | - | - | - | 0.49M | 0.13M |
| Net income | 0.49M | 1.36M | -0.04M | -7.52M | -0.33M |
| Change in cash | 0.24M | 0.27M | 0.78M | 0.08M | 0.27M |
| Begin period cash flow | 1.40M | 1.14M | 0.36M | 0.27M | 0.00M |
| End period cash flow | 1.64M | 1.40M | 1.14M | 0.36M | 0.27M |
| Total cash from operating activities | 0.28M | 0.58M | 0.97M | 0.03M | 0.35M |
| Issuance of capital stock | - | - | 0.00M | 0.03M | 0.00M |
| Depreciation | 0.14M | 0.10M | 0.07M | 0.07M | 0.00M |
| Change to inventory | 0.00M | 0.00M | 0.00M | -0.00M | -0.00M |
| Change to account receivables | 0.12M | -0.03M | - | -0.02M | -0.04M |
| Change to netincome | - | - | - | 6.78M | -0.04M |
| Capital expenditures | 0.06M | 0.31M | 0.13M | 0.11M | 0.07M |
| Change in working capital | -0.40M | -0.94M | 0.43M | 0.70M | 0.71M |
| Stock based compensation | - | 0.00M | 0.38M | 6.74M | 0.00M |
| Other non cash items | 0.04M | 0.05M | 0.06M | 0.09M | 0.01M |
| Free cash flow | 0.22M | 0.28M | 0.84M | -0.08M | 0.28M |
Sector: Healthcare Industry: Diagnostics & Research
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| LDDD Longduoduo Company Limited |
- -% |
0.51 | - | - | 7.18 | 20.77 | 6.64 | 45.50 |
| TMO Thermo Fisher Scientific Inc |
-17.51 2.54% |
671.24 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.25 0.11% |
220.36 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| WUXIF WuXi AppTec Co. Ltd |
- -% |
23.77 | 22.29 | 17.95 | 1.53 | 5.98 | 8.39 | 14.30 |
| WUXAY WuXi AppTec Co. Ltd |
-0.92 3.87% |
22.85 | 23.28 | 18.73 | 1.51 | 6.24 | 8.39 | 14.30 |
Longduoduo Company Limited, together its subsidiaries, provides preventive healthcare solutions in the People's Republic of China. The company offers range of preventive healthcare services, including disease screening, healthcare treatments, healthcare products, and other services for the prevention of myocardial infarction, cerebral infarction, hemiplegia, and cardiovascular and cerebrovascular diseases through third-party healthcare service providers, product suppliers, and sales agents. It also provides meridian-regulating and consciousness restoring iatrotechnics; double blood purification; immunological ozonated autohemotherapy; platelet-rich plasma; relaxation therapy; vegetative nerve regulation; and microwave therapy. The company was founded in 2020 and is headquartered in Hohhot, China.
| Name | Title | Year Born |
|---|---|---|
| Mr. Huibo Xu | President & Chairman | 1983 |
| Ms. Hongxiao Zhou | CEO, Secretary & Director | 1976 |
| Ms. Liping Kang | Chief Financial Officer | 1983 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.